Trastuzumab Subcutaneous 21 days - Early Breast Cancer. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Trastuzumab Subcutaneous 21 days - Early Breast Cancer, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).	1
HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with PACLitaxel or DOCEtaxel.	2
HER2 positive early breast cancer (EBC) in combination with adjuvant chemotherapy consisting of DOCEtaxel and CARBOplatin.	1
HER2 positive early breast cancer (EBC) in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy, for locally advanced (including inflammatory) disease or tumours >2cm in diameter.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab